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➢1976: Controlled drug release polymer carriers
➢1978: thermosensitive liposomes were first used for drug delivery
➢1980: Ph stimuli drug delivery system




• uncontrolled growth of abnormal cells
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Some conventional treatment methods
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Repeated dose administration ( indicated by arrows) over time
Image source: doi: 10.26717/BJSTR.2018.11.002056
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treatment diagnosisprevention
Nanomedicine & Nanocarriers ( Modern Therapy)
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Advantages of using nanocarriers
➢Specifically target cancer tissue/ specific localization






Typical drug release profile from a drug delivery system.
There is a sustained release of the drug over time
Image source: doi: 10.26717/BJSTR.2018.11.002056
Discussion
14Image source: www.precisionnanosystems.com
Smart Drug Delivery Systems (SDDSs)
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Smart (stimuli–responsive) nanocarriers 
which carry anti-cancer drugs to the 
cancer site
Targeting mechanisms to locate the 
cancerous site 
stimulus techniques to release the 






































Polymer-based Lipid-based non polymeric
• Dendrimers












• Silica based NPs
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Pie chart showing 
relative distribution of 
nanomaterials used in 
drug products that were 
submitted to the FDA 

































low cost of 
preparation






arising due to 





➢colloidal particles (10-1000nm) 
➢Produced relatively easily
➢drug is dissolved, entrapped, encapsulated or attached to a NP matrix.( 
protect them from enzymatic and hydrolytic degradation)
➢obtained from natural, semi-synthetic or synthetic polymers.
➢Longer clearance times
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• extremely stable in the biological fluid
• reduces the side effects of a given drug
26
Biodegradable polymers
• undergo degradation, non-enzymatically and enzymatically 
• generate a harmless, biocompatible by-product.
• have no constant inflammatory effect
• good permeability
• good therapeutic properties
27
✓derived from a wide range of plant- or animal-based sources
✓Abundant in nature
✓Biodegradable & biocompatible
✓ low cytotoxic effects
28
















• most widely used natural 
polymer for drug delivery
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• relatively long drug release period
• nontoxic nature
• ease of modification





Hydrophobic polymers (core) hydrophilic polymers (shell)
poly caprolactone (PCL) poly ethylene glycol (PEG) 
poly lactic-co-glycolic acid (PLGA) Poly(glycolic acid) (PGA)
poly lactic acid (PLA) poly ethyleneimine (PEI) 
poly aspartic acid (PAsp) poly acrylamide (PAM)





Most popular biodegradable 






(by adjusting the ratio of PLA:PGA & 
their molecular weights)
➢ more stable against hydrolysis
➢ cross blood-brain barrier (BBB) 
➢ The acid nature of PLGA monomers 
are not suitable for certain drugs












➢ rapid degradation rate
(incorporated with other polymers 
such (PCL) and (PLA))
➢ insolubility of PGA in most of the 
solvents
➢ non-toxic behavior
➢ Inexpensive and easy to construct
• was marketed as the first 
biodegradable synthetic polymers
38




































➢starts immediately upon i.v. administration into the circulatory system
➢Particles rapidly adsorb plasma proteins onto their surface
➢This protein adsorption results in the formation of a protein corona
➢Protein corona formation is a dynamic process
➢will modify their physicochemical property and bioavailability 
➢ultimately, determine the host immune response
39
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Schematic representation of protein corona developed on the surface of 
























Cancer cell targeting mechanisms
❑Passive targeting
▪ non-specifically release of NPs from blood vessels to tumoral tissues 
▪ By the enhanced permeation and retention effect (EPR-effect)
▪ The permeable lining of blood vessels through inflammatory state or 
hypoxia 
▪ through convection or passive diffusion
▪ strongly dependent on particle size 
41
❑Active targeting
▪ Attachment of a specific ligand, ab, aptamer or peptide to the carriers
▪ Selected ligand based on the type of receptor that is in tumor cells
▪ selective recognition of the targeted cells
▪ Specific ligand-receptor interaction
42
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➢Cell uptake studies in the presence of inhibitors help us understand the cell 
entrance mechanisms of NPs
Image source: doi: 10.18433/jpps30318






size and shape of the particles affect their:
➢circulation time
➢the clearance rate of the particles from the body
➢protein corona formation on their surface
➢ margination and binding to the vascular wall
➢drug release profile
48
Particles Size & shape
▪ Optimal NP uptake size depend on the cell being assayed
▪ large enough to prevent from leakage into the blood capillaries
▪ small enough to escape from macrophages located in RES
▪ diameter between 1-100 nm have better pharmacokinetic properties
▪ decreasing the surface area to volume ratio of the nanoparticles
▪ Spherical nanoparticles are a good option for drug delivery
49
Surface Properties
• Use hydrophilic polymers such as PEG to reduction phagocytosis & 
plasma proteins.
• Positively charged nanoparticles are taken up at a faster rate









































































Due to Altered Cancer Cell Metabolism 



























1. Polymers become protonated under acid environment of tumors (pH 6.5)
➢structural damage of the polymers & specific release of their payload
55Image source: doi.org/10.1016/j.jsps.2020.01.004
2. introduce cleavable acid-responsive bonds in the structure of nanocarriers.

































temperature-responsive polymeric nanocarriers 
• Temperature may be an external or internal stimulus.
• these polymers synthesized according to lower critical solution temperature 
(LCST) feature.
• T > LCST                polymeric chain becomes dehydrated & more 
hydrophobic            structural damage of the polymers                                 































Redox potential-responsive polymeric nanocarriers
• Based on glutathione (GSH) (a powerful reducing agent) concentration in 
cancerous tissues
(100 times > healthy physiological tissues)
• Redox potential-responsive polymers possess disulfide bonds.














































• many cancers often display the overexpression of different kinds of enzymes
• enzymes trigger the release of a drug by breaking certain bonds in nanocarriers
• example: PEG2000-peptide-PTX  cleaved by matrix metalloproteinase (MMP)
• Lysosomes possess abundant digestive enzymes (sulfatases and glycosidases)
• attachment of drugs with lysosomally cleavable peptides as spacers.
61
Light-responsive polymeric nanocarriers
• light is introduced in photosensitive nanocarriers through a linker
• the linker can be broken exposed to light irradiation with a proper wavelength
• drug release mechanism upon irradiation stimulation.
• various wavelengths of light (ultraviolet, near- infrared(NIR), visible) reported
• NIR spectrum is  preferred ( safety and strengthened tissue penetration)
62
• based on the conversion of light to heat via a photo-thermal agent




Image source: doi: 10.1016/B978-0-08-101997-9.00004-7
• Via two-photon irradiation with laser
• simultaneously absorbed of two photons of equal or different frequencies
• excitation of a molecule from its ground state to a higher energy state
• nanocarriers disintegrated and release drug
65
two-photon absorption (TPA) method
Dual-responsive polymeric nanocarriers
• nanocarriers that respond to a combination of two signals






stimuli responsive nanoparticles for anti-cancer drug release.
68
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Fastest Growing Market: Asia Pacific 






















PNPs✓ polymer-based DDSs are 
optimal candidates for site-
triggered drug delivery.
Conclusions
✓Smart DDSs :able to 
respond to biological 
stimuli (characteristic of 
the target site)
further research into safer and 
more biocompatible delivery 
systems is still warranted.
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